Misinformation, disparagement, opacity and throttling – how far does the ‘special responsibility’ go?

What links a multiple sclerosis drug ingredient, trains tickets in the South of England and iPhone batteries? Very little you might say? But in fact these subjects are all bound up in what some believe to be an ongoing extension to the frontiers on the law on abuse of dominance. Just how far does the … Continue reading Misinformation, disparagement, opacity and throttling – how far does the ‘special responsibility’ go? →

Antitrust and private equity – parental liability rules can allow authorities to claw back profits in UK and Europe

Private equity (PE) is in focus for antitrust authorities. In a merger control context, concerns around roll-up and keeping the bigger picture in mind occupy both Jonathan Kanter at the DOJ and Lina Khan at the FTC. My colleague Stijn Huijts covered this in his 13 June 2022 blog. Consideration of the PE angle is … Continue reading Antitrust and private equity – parental liability rules can allow authorities to claw back profits in UK and Europe →

Phenytoin – was it worth it?

On 21 July 2022 the CMA imposed fines of £63m on Pfizer and £6.7m on Flynn in relation to the excessive pricing of the generic drug phenytoin, an anti-epilepsy drug. This comes nearly six years on from the CMA’s first infringement decision in relation to the conduct. That first decision imposed fines of £84.2m on … Continue reading Phenytoin – was it worth it? →

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31